XLON
HIK
Market cap4.56bUSD
Jul 10, Last price
1,584.00GBP
1D
-1.92%
1Q
19.82%
Jan 2017
-16.32%
IPO
461.70%
Name
Hikma Pharmaceuticals PLC
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hikma Pharmaceuticals PLC is a global pharmaceutical company that specializes in the development, production, commercialization, and distribution of a wide array of generic, branded, and in-licensed medicines. These pharmaceuticals are provided in various final dosage forms, including solid, semi-solid, liquid, and injectable formats. The company's business activities are organized into three core divisions: Injectables, Generics, and Branded products. The Injectables division primarily supplies generic injectable medications for hospital use. Its Generics segment focuses on offering oral and other non-injectable generic formulations to the retail market. The Branded segment, conversely, delivers branded generic drugs and products licensed from third parties to both retail consumers and hospitals. Hikma's product portfolio addresses numerous therapeutic areas, such as anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory illnesses. The company maintains a substantial international footprint, operating throughout the United Kingdom, the United States, the Middle East, North Africa, Europe, and other global markets. Founded in 1978, Hikma Pharmaceuticals PLC has its headquarters in London, UK.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||